Dr. Sara Pai is a lead researcher of HPV oropharyngeal cancer at Harvard Medical School and practices otolaryngology at Massachusetts General Hospital. She is a former associate professor at Johns Hopkins School of Medicine, Department of Otolaryngology – Head and Neck Surgery (ranked #1 in the U.S.) and an active researcher on HPV oropharyngeal cancer.

Dr. Pai is working on ongoing and future clinical trials. To find out more about enrolling in one of these clinical trials, email Dr. Sara Pai.

physicians-update

CLINICAL TRIAL #1 | HPV VACCINE STUDY

CLINICAL TRIAL #1 IS CURRENTLY CLOSED.
CHECK BACK FOR A NEW HPV VACCINE STUDY COMING SOON.

This trial is for patients who are newly diagnosed with HPV+ head and neck cancer. After they receive chemoradiation therapy to treat their cancer, they receive 3 doses of the vaccine to boost their immune system to recognize HPV and any HPV-infected cells. We are enrolling only 21 patients into this study. We do need to meet the patient before he/she starts treatment for their head and neck cancer to determine what their baseline immune responses are against the virus before vaccination.

VIDEO | CLINICAL TRIAL #1

CLINICAL TRIAL #2 | ANTI-PD-1 STUDY

A new study published in March describes why HPV infects the tonsil as well as new therapies on how to reverse the immune system against the virus. The paper, Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma, is the basis of a new clinical trial using anti-PD-1 for this patient population. PD-1 stands for “programmed cell death protein 1.” Therapies targeting PD-1 may augment immune responses to viruses such as HPV.

Dr. Sara Pai:

This trial is for open to patients with locally recurrent and/or metastatic head and neck cancer, either HPV + or HPV -.

NOTE: Unless attributed to a doctor or medical organization, all views on HPVANDME.ORG are published from personal experience only and not intended to be any form of medical advice.
Always consult your doctor.